Statement: 1 patient in the primary trial had an abrupt loss of heart function.
Primary_evidence: Adverse Events 1:   Total: 146/573 (25.48%)   Anaemia 4/573 (0.70%)   Disseminated intravascular coagulation 0/573 (0.00%)   Neutropenia 1/573 (0.17%)   Thrombocytopenia 0/573 (0.00%)   Acute coronary syndrome 1/573 (0.17%)   Angina pectoris 1/573 (0.17%)   Atrial fibrillation 2/573 (0.35%)   Atrial flutter 0/573 (0.00%)   Cardiac arrest 1/573 (0.17%)   Cardiac failure 0/573 (0.00%) Adverse Events 2:   Total: 101/570 (17.72%)   Anaemia 3/570 (0.53%)   Disseminated intravascular coagulation 1/570 (0.18%)   Neutropenia 1/570 (0.18%)   Thrombocytopenia 1/570 (0.18%)   Acute coronary syndrome 0/570 (0.00%)   Angina pectoris 1/570 (0.18%)   Atrial fibrillation 0/570 (0.00%)   Atrial flutter 1/570 (0.18%)   Cardiac arrest 0/570 (0.00%)   Cardiac failure 1/570 (0.18%)